Neolight develops the Skylife™ Neonatal Phototherapy System, which utilizes exceptional spectral power to effectively treat jaundice in both pre-term and full-term infants. The system enhances neonatal care by providing targeted light therapy that accelerates bilirubin reduction, improving patient outcomes.
Funding
$2.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neonatal jaundice, a common condition in newborns, requires effective phototherapy treatment to reduce bilirubin levels and prevent potential complications. Traditional phototherapy systems may lack the spectral power needed for efficient bilirubin reduction, potentially prolonging treatment duration and hospital stays.
Solution
Neolight develops the Skylife™ Neonatal Phototherapy System, engineered to deliver exceptional spectral power for the effective treatment of jaundice in both preterm and full-term infants. The system utilizes targeted light therapy to accelerate bilirubin reduction, leading to improved patient outcomes and reduced treatment times. By optimizing the light spectrum and intensity, the Skylife™ system enhances the efficiency of phototherapy, promoting faster recovery and minimizing the need for extended hospital stays.
Target Audience
The primary users are hospitals, neonatal intensive care units (NICUs), and healthcare providers specializing in newborn care.
Features
- High-intensity light source optimized for bilirubin absorption
- Precise spectral control to maximize therapeutic effect
- Uniform light distribution to ensure consistent treatment
- Compact design for easy integration into neonatal care environments